ClinicalTrials.gov
public full text
Public Domain
"Efesovir" (FS-1) for COVID-19, Phase 2
Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19. The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19#1371676
- Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections#1213980
- To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants#1246968
- ESICM UNITE COVID-19 Project (UNITE-COVID)#1125401
- Favipiravir in High-risk COVID-19 Patients#1075720
Record · ID 1232043
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive